

1 **Robust metabolomic age prediction based on a wide selection of metabolites**

2 Key words: metabolomics, ridge regression, prediction, aging, xenobiotics

3 Tariq Faquih¹, Astrid van Hylckama Vlieg¹, Praveen Surendran^{2,3,4,5,6}, Ruifang Li-Gao^{1,7}, Renée de
4 Mutsert¹, Frits R. Rosendaal¹, Raymond Noordam⁸, Diana van Heemst⁸, Ko Willems van Dijk^{9,10,11},
5 Dennis O. Mook-Kanamori^{1,12}

6 ¹ Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands;
7 T.O.Faquih@lumc.nl (T.O.F.); A.van.Hylckama.Vlieg@lumc.nl (A.v.H.V.); R.Li@lumc.nl (R.L.-G.);
8 R.de.Mutsert@lumc.nl (R.d.M); F.R.Rosendaal@lumc.nl (F.R.R.);
9 D.O.Mook@lumc.nl (D.O.M.-K.)

10 ² British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary
11 Care, University of Cambridge, Cambridge, UK; ps629@medschl.cam.ac.uk (P.S.)

12 ³ British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK;
13 ps629@medschl.cam.ac.uk (P.S.)

14 ⁴ Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge,
15 Cambridge, UK; ps629@medschl.cam.ac.uk (P.S.)

16 ⁵ Rutherford Fund Fellow, Department of Public Health and Primary Care, University of Cambridge,
17 Cambridge, UK; ps629@medschl.cam.ac.uk (P.S.)

18 ⁶ GSK plc., Stevenage, England, United Kingdom

19 ⁷ Metabolon, Inc., Morrisville, North Carolina, United State of America; R.Li@lumc.nl (R.L.-G.)

20 ⁸ Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical
21 Center, Leiden, The Netherlands; R.Noordam@lumc.nl (R.N.); D.van.Heemst@lumc.nl (D.v.H.)

22 ⁹ Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands;
23 K.Willems_van_Dijk@lumc.nl (K.W.v.D)

24 ¹⁰ Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center,
25 Leiden, The Netherlands; K.Willems_van_Dijk@lumc.nl (K.W.v.D)

26 ¹¹ Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center,
27 Leiden, The Netherlands; K.Willems_van_Dijk@lumc.nl (K.W.v.D)

28 ¹² Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The
29 Netherlands; D.O.Mook@lumc.nl (D.O.M.-K.)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 **Abstract**

31 Chronological age is a major risk factor for numerous diseases. However, chronological age does not
32 capture the complex biological aging process. Biological aging can occur at a different pace in
33 individuals of the same chronological age. Therefore, the difference between the chronological age
34 and biologically driven aging could be more informative in reflecting health status. Metabolite levels
35 are thought to reflect the integrated effects of both genetic and environmental factors on the rate of
36 aging, and may thus provide a stronger signature for biological age than those previously developed
37 using methylation and proteomics. Here, we set out to develop a metabolomic age prediction model
38 by applying ridge regression and bootstrapping with 826 metabolites (of which 678 endogenous and
39 148 xenobiotics) measured by an untargeted high-performance liquid chromatography mass
40 spectrometry platform (Metabolon) in 11,977 individuals (50.2% men) from the INTERVAL study
41 (Cambridge, UK). Participants of the INTERVAL study are relatively healthy blood donors aged 18-75
42 years. After internal validation using bootstrapping, the models demonstrated high performance with
43 an adjusted R^2 of 0.82 using the endogenous metabolites only and an adjusted R^2 of 0.83 when using
44 the full set of 826 metabolites with age as outcome. The latter model performance could be indicative
45 of xenobiotics predicting frailty. In summary, we developed robust models for predicting metabolomic
46 age in a large relatively healthy population with a wide age range.

47 **Introduction**

48 Chronological age is a major risk factor for a multitude of diseases (1, 2). The biology of aging
49 comprises complex and multifactorial processes that are influenced by genetic, lifestyle and
50 environmental factors (3-5). Evidently, the rate of biological aging varies between individuals, as in
51 contrast to other individuals of the same age group, wherein, some individuals are able to live to an
52 older chronological age without age-related diseases and disability (3). This suggests that
53 chronological age does not align with the biological aging process. For this reason, several studies have
54 aimed to capture the signature of biological changes due to aging process by predicting its rate based
55 on biological factors using, for example, DNA methylation (6) and proteins (7).

56 Metabolomic profiling aims to identify small molecules that are mostly substrates or products of
57 metabolism (metabolites). The number of metabolomics studies has increased in recent years due to
58 major technological advances and the availability of (validated and high throughput) commercial and
59 noncommercial analyses platforms. In addition, the current platforms have improved their capability
60 to detect and quantify large numbers of endogenous and xenobiotic metabolites(8, 9). Since individual
61 metabolomic profiles reflect the influences of both genetic and acquired factors, they are thought to
62 provide a more holistic representation of biological processes, such as aging (8, 9). Furthermore, as

63 metabolomic profiles are strongly affected by chronological age (4, 10) and sex (11, 12), they have
64 been used to develop prediction models of chronological age (i.e., the metabolomic age) (13-16).
65 However, predicting metabolomic age using metabolomics had limited success or faced
66 methodological limitations due to several reasons. First, some studies used a relatively small sample
67 size to predict age using hundreds or even thousands of metabolite predictors (10, 17). The inclusion
68 of a larger number of predictors than the number of samples may cause overfitting and bias. Second,
69 previous metabolomic age studies used targeted platforms, such as the Nightingale platform, that
70 specifically measure a small number of lipoproteins and some low-molecular metabolites. This limits
71 the variety of the metabolites and the information used for the prediction of age. Third, studies may
72 be limited by the age distribution of the cohort study. This may restrict the model to a specific age
73 range which affects the generalizability of the model in other studies and other age groups (10).
74 Fourth, generalizability may also be reduced if the model is developed in cohorts with an oversampling
75 of individuals with specific disease outcomes or specific population characteristics (7, 13). Fifth,
76 statistical methodology such as stepwise selection, have been reported to cause overfitting of the
77 prediction model (18). Finally, it is challenging to examine the model's validity and generalizability in
78 external studies or different populations particularly due to the dynamic nature of metabolite levels
79 (19-21).

80 In this study, we aimed to develop a model to predict metabolomic age in a large healthy population
81 with a widespread age range, using a single untargeted metabolomics platform. To attain this goal,
82 we developed a prediction model using data from the INTERVAL study (22) (University of Cambridge,
83 Cambridge, UK). Metabolomic profiles were available in 11,977 participants as measured using
84 Metabolon's (Durham, North Carolina, USA) untargeted metabolomics platform. These
85 measurements included a broad range of endogenous and xenobiotic metabolites (n=1,363) from
86 various biochemical pathways, thereby enabling the capture of metabolites related to a vast range of
87 ageing effects.

88 **Methods**

89 **INTERVAL Study**

90 The INTERVAL study is a prospective cohort study of approximately 50,000 participants nested within
91 a pragmatic randomized sample of blood donors (22). Between 2012 and 2014, blood donors, aged
92 18 years and older, were consented and recruited from 25 National Health Service Blood and
93 Transplant (NHSBT) static donor centers across the UK. The INTERVAL study was approved by The
94 National Research Ethics Service (11/EE/0538). Individuals with major disease (myocardial infarction,

95 stroke, cancer etc.) as well as those who reported being unwell or having had recent illness or infection
96 or did not fulfill the other criteria required for blood donation (22, 23) were ineligible for the study.
97 Therefore, participants included in the study were predominantly healthy. Participants completed
98 online questionnaires addressing basic lifestyle and health-related information, including self-
99 reported height and weight, ethnicity, smoking status, alcohol consumption, doctor-diagnosed
100 anemia, use of medications (hormone replacement therapy, iron supplements) and menopausal
101 status (22). Untargeted metabolomic data were available in 11,979 individuals (age range 18 - 75).
102 Two individuals had incorrect or missing height/weight values and were therefore excluded from the
103 study. Thus, the final sample size for the current study was 11,977.

104 **Untargeted metabolomic measurements**

105 Untargeted metabolomic measurements were quantified at Metabolon Inc. (Durham, North Carolina,
106 USA) using Metabolon™ Discovery HD4 platform. In brief, this process involves four independent ultra-
107 high-performance liquid chromatography mass spectrometry (UHPLC-MS/MS) platforms (24, 25). Of
108 these platforms, two used positive ionization reverse phase chromatography, one used negative
109 ionization reverse phase chromatography, and one used hydrophilic interaction liquid
110 chromatography negative ionization (25). Known metabolites were annotated at Metabolon Inc. with
111 chemical names, super pathways, sub pathways, biochemical properties, and compound identifiers
112 from various metabolite databases. Metabolomic measurements in the INTERVAL study were
113 conducted in three batches (n=4087, 4566, and 3326). Subsequent harmonization and quality checks
114 were performed between the batches by Metabolon. All metabolite measurements were scaled to a
115 median of 1.

116 **Selection of Predictors**

117 We aimed to select metabolites consistently and reliably measured by the Metabolon platform. In
118 total 1,411 metabolites were measured in the INTERVAL study. First, we removed metabolites
119 completely missing in at least one of the batches (n=175). Second, we excluded metabolites without
120 annotation (unnamed metabolites) (n=258), keeping only endogenous and xenobiotic metabolites.
121 These metabolites were excluded as they are inconsistently measured by the platform and are highly
122 variable between batches and studies. Moreover, the lack of full annotation increases the uncertainty
123 that we are using the same metabolite across batches and studies and leaves no secondary
124 information for further verification. Third, we excluded metabolites measured in less than 100
125 individuals (n=30). Fourth, to ensure that the metabolites that are used for our model are not unique
126 for the INTERVAL study, we cross-referenced our dataset with an independent study with Metabolon

127 measurements. For this we used the Netherlands Epidemiology of Obesity (NEO) study, a population-
128 based (n=599) cohort study of individuals aged 45–65 years (26, 27). Based on this comparison, we
129 additionally excluded 122 metabolites that were not detected in the NEO study. The final set of
130 metabolites included 826 metabolites, with 678 endogenous and 148 xenobiotic metabolites that
131 were confirmed to be regularly measured by the Metabolon platform (Figure 1).

132 **Missing value imputation**

133 Missing values were imputed using the pipeline as described in our previous work (27). In brief,
134 endogenous metabolites were imputed by multiple imputation using chained equations method to
135 generate five imputed datasets (m=5). For each metabolite with missing values, we used the outcome
136 variable (i.e., age), 5-10 highly correlated related metabolites, body mass index (BMI), center number
137 where the blood samples were collected, and the batch number to impute the missing values.
138 Xenobiotic metabolites were imputed to zero to account for true missingness.

139 **Model Development**

140 For the development of the model, we used ridge regression (28) to reduce potential overfitting. Cross
141 validation was performed (n=10) in each imputed dataset to calculate the optimal shrinkage term
142 (λ). Subsequently the mean of the λ values was used to develop the model on the stacked
143 imputed datasets (i.e., all 5 datasets combined as one). Accordingly, the weight of the observations in
144 the stacked dataset was set to $1/m = 1/5 = 0.2$ (20). As the outcome (age) is a continuous variable, we
145 assessed the fit of the model by deriving the R^2 . As an additional sensitivity test, we used generalized
146 additive model (GAM) to examine and calculate the R^2 for the nonlinear correlation. Internal validation
147 was performed using bootstrapping (b=100). Bootstrapping results were used for the optimization of
148 R^2 and the calculation of the mean squared error (MSE) and the mean absolute error (MAE) of the
149 model. Two models were developed using two sets of the selected metabolite predictors. First, we
150 used the full set of endogenous and xenobiotic metabolites (n=826) to develop “model A”. Second,
151 we used only the endogenous metabolites (n=678) to develop “model B”. As previous studies found
152 that metabolomic profiles (12, 29) and aging (30-32) are influenced by the sex of individuals, we
153 included sex as an additional predictor in both models.

154 **Sample size considerations**

155 The primary database used to create the prediction model was the INTERVAL study (n= 11,977) with
156 826 predictors. We used the formulas described by Riley et al. (33) to confirm that our sample size (n)
157 and number of predictor (p) are sufficient to minimize overfitting and provide high prediction
158 precision. First, we calculated Copas global shrinkage factor for our data (34, 35) to see if it is above

159 the recommended 0.9 threshold (33). Based on this calculation the estimated shrinkage factor was
160 0.95 if the adjusted R^2 of the model was assumed to be 0.7. Second, we calculated the sample size
161 required to ensure a small difference between the R^2 and the adjusted R^2 for the development model.
162 Assuming the adjusted R^2 was 0.7 again and a small desired R^2 difference ($R^2_{diff}=0.025$), then the
163 sample size required to achieve this should be at least $n=9913$. Third, we checked the sample size
164 required for precise residual standard deviation of the model. Accordingly, we found the multiplicative
165 margin of error (MMOE) to be less than 10% (MMOE = 1.3%) using our n and p in the INTERVAL study.
166 Finally, we checked the precision of the mean predicted outcome value (predicted age) of the model.
167 We used n and p for the INTERVAL study and assumed that predicted age would have a mean of 45
168 and a variance of 35. Accordingly, the upper and lower bounds were approximately 45.34 and 44.65
169 respectively. Thus, the MMOE for the mean predicted outcome was less 1% (MMOE = $45.34 / 45 =$
170 $1.007 = 0.7\%$). Therefore, the sample size of the INTERVAL study was optimal to minimize overfitting,
171 optimism, and provide a precise estimation of the residual standard deviation and mean predicted
172 values.

173 **Results**

174 **Population characteristics**

175 Characteristics of the total INTERVAL study population and age subgroups are summarized in Table 1.
176 In total 11,977 individuals were included and had a normal age distribution with a mean age of 45
177 years and a range of 18 – 75 years. The number of men and women was approximately equal (50.2%
178 were men). BMI was largely in the recommended range of 18.5-24.9 kg/m² (36) with a mean BMI of
179 22.8 kg/m² and was similar in all age groups.

180


	Total	18 to 25	25 to 35	35 to 45	45 to 55	55 to 65	65 to 75
N	11977	1178	2245	2152	2867	2602	811
Age (years), mean (range)	45 (18-75)						
Men, n (%)	6019 (50.2%)	485 (41.2%)	965 (42.3%)	1042 (48.4%)	1560 (54.4%)	1480 (56.9%)	546 (67.3%)
BMI (kg/m ²), mean (SD)	22.8 (4.2)	21.3 (4.0)	22.0 (4.2)	23.3 (4.4)	23.5 (4.3)	23.0 (3.9)	22.6 (3.5)

181 Table 1. Characteristics of the INTERVAL study population.

182 **Metabolomic Age Prediction**

183 Prediction models A (endogenous plus xenobiotic metabolites) and B (endogenous metabolites only)
184 were developed in the INTERVAL study using ridge regression. The workflow including metabolite
185 selection, missing value imputation, and analyses are summarized in Figure 1. Internal validation using
186 bootstrapping (resampling n = 100) and optimization provided an R² of 0.83 (MSE=31, MAE=4.4) for
187 model A, and 0.82 (MSE=33.7, MAE=4.6) for model B. The R² for the generalized additional model
188 (GAM) were slightly higher for both models, 0.85 for model A and 0.84 for model B (Figure 2,
189 Supplementary Table 1, Supplementary Figure 1). Full tables with the intercept, sex and metabolite
190 coefficients for model A and B are provided in Supplementary Table 2. This table also contains the
191 mean values for the metabolites from the INTERVAL study.

192




193

194

195

Figure 1: Flowchart of the selection of predictor metabolites and the development steps for the metabolomic age prediction model in the INTERVAL study



196

197 Figure 2: Correlation plots of the Metabolomic age (predicted age) on the horizontal axis and the
198 chronological age on the vertical axis for model A (A) and model B (B). The data used is the stacked
199 imputed datasets in the INTERVAL study. Abbreviations: GAM, generalized additive model.

200 Discussion

201 In this study, we developed a prediction model for metabolomic age based on metabolite
202 measurements, including a wide range of endogenous and xenobiotic metabolites belonging to a
203 variety of biochemical pathways. The metabolomic measurements were performed in a single study
204 using the same metabolomic platform and harmonized for within study and between batch variation.
205 Importantly, we used multiple imputation, ridge regression, and bootstrapping (20) to develop and
206 internally validate the metabolomic age prediction models. We developed two models, with the first
207 model A using both endogenous and xenobiotic metabolites ($n=826$), and the second model B using
208 the endogenous metabolites only ($n=678$). Both models had high adjusted R^2 (model A = 0.83; Model
209 B = 0.82), however, model B had slightly higher MSE and MAE, indicating higher error for the predicted
210 values.

211 Ridge Regression for Metabolomic Age

212 Our metabolomic age model is based on ridge regression which generates shrinkage factors that
213 shrink metabolite coefficients with weak influence on the model to small values. Unlike methods such
214 as LASSO and elastic net regression, this shrinkage never causes the coefficients to reach zero.
215 Therefore, unlike those methods, ridge regression does not perform selection of predictors, in this
216 case metabolites, due to the shrinkage term. Thus, the model consistently includes the same
217 metabolites during the cross validation and internal validation by bootstrapping (20). Ridge regression

218 thus ensures rigorousness and consideration of all the selected metabolite predictors. In addition, we
219 found in our model that nonlinear GAM R^2 to be slightly higher than linear R^2 in both models. Figure 2
220 also shows that the GAM line curves at the edges of the age ranges. Therefore, predicting
221 metabolomic age from this model in a nonlinear form, by adding a quadratic term or using a spline
222 function, may further expand the model flexibility.

223 **Strengths and Limitations**

224 A major strength of our current study is the development of robust metabolomic age prediction
225 models based on a large number of metabolites measured in a large cohort with a wide age
226 distribution. This sample size was confirmed to fit the required criteria for developing a model with
227 low overfitting (33). Furthermore, the INTERVAL study included relatively healthy blood donors as
228 participants. Blood donors are prescreened for a number of common diseases, making it a suitable
229 study to develop a metabolomic age without being affected by specific disease-related effects on
230 metabolites. Unlike previous metabolomic age predictors (alternatively referred to as metabolomic
231 “clocks”), we developed our model using the latest Metabolon metabolomics platform that measures
232 a large selection of metabolites. An advantage of this platform is the inclusion of xenobiotics, such as
233 those derived from medication or pollution as well as endogenous metabolites. Thus, we were able to
234 include metabolites originating from various internal and external sources. The xenobiotic metabolites
235 represent some of the acquired environmental and lifestyle exposures of individuals that could play a
236 role in biological aging. For example, medication metabolites could be a predictor of frailty. However,
237 our study has two limitations. First, because the INTERVAL study does not have data for health-related
238 outcomes, we could not assess the effects of different disease outcomes and health phenotypes on
239 the metabolomic age. Second, as the INTERVAL study used here was cross sectional, we could not
240 examine the model overtime or examine the ability of metabolomic age to predict disease outcomes
241 or mortality in a future time point.

242 **External Validation for Metabolomic Age and Future Applications**

243 Prediction models may suffer from overfitting due to selection bias, small sample size, methodology
244 limitations, and lack of internal validation and calibration during development. However, another
245 common issue regarding prediction modelling, such as the case with metabolomic age, is the challenge
246 to externally validate them. This a common issue with prediction models in general. Indeed, few
247 studies perform external validation of prediction models (19, 37). The reasons for the lack of external
248 validation include the difficulty of applying and reproducing the prediction model method, lack of the
249 full prediction variables to develop the model in the new dataset, or a lack of an appropriate sample

250 size for external validation. Without external validation, the quality of the models cannot be properly
251 assessed, and a model could still be overfitted despite presenting good results during internal
252 validation(20, 21, 38). We took advantage of the sample size and wide age range to use a stringent
253 ridge regression and internal validation method to develop the metabolomic age model. The resulting
254 model demonstrated a high R^2 for the metabolomic age. The high R^2 from our models is unlikely to be
255 due be overfitting as we considered and calculated the power and sensitivity of the model based on
256 the sample size and number predictors (33), in addition to the rigorous prediction modelling
257 methodology. The metabolomic age was able to predict chronological age well but not perfectly. The
258 missing 0.2 from R^2 is likely a reflection the biological aging process captured by the metabolomic age.
259 However, future robust external validation, using weak and moderate calibrations in other
260 populations (38) would be valuable for the metabolomic age models presented in this paper.

261 Several age prediction models have been developed that utilize different biological measurements
262 such as targeted metabolomics (7, 14), proteomics (7), and epigenetics (DNA methylation)(6). These
263 studies have reported that the metabolites were a strong predictor of body mass index, metabolic
264 syndrome, cancer (7), type 2 diabetes, and cardiovascular disease (14). Furthermore, other biological
265 clocks using proteomics and epigenetics were reported to be associated with depression and other
266 outcomes (7). Therefore, it will be valuable to apply the prediction models presented in this paper in
267 large longitudinal cohorts and examine the metabolomic age in relation to calendar age with the
268 aforementioned phenotypes and other health related outcomes. Assessing the association between
269 the residual between the chronological and metabolomic age with disease and health phenotypes
270 overtime will provide clinically relevant prediction. The prediction strength will indicate the
271 robustness of our model and provide the means to for external validation and re-calibration of the
272 model.

273 In addition to our aim of addressing primary issues of the development of metabolomic age models,
274 the Metabolon platform is expanded on the range of metabolites that can potentially be a better
275 predictor of age. For example, previous metabolomic age studies have not measured or included
276 xenobiotic metabolites. In our study, we were able to include this additional group of metabolites in
277 model A. Furthermore, Model A may also be used in tandem with metabolomic age from targeted
278 platforms, and biological clocks of different biological molecules measurements, similar to the work
279 by Jansen et al. (7), to possibly improve or compare their predictive performance and their ability of
280 capturing the effects of health-related phenotypes.

281 **Conclusions**

282 We developed metabolomic age prediction models in a large relatively healthy population using a
283 wide array of endogenous and xenobiotic metabolites. In model A with the endogenous and
284 xenobiotic metabolites and in model B with endogenous metabolites only, the R^2 of the linear fit was
285 0.82 and 0.83, respectively. We provided the full list of metabolites and their coefficients for both
286 models. This data can enable other researchers to replicate our metabolomic age prediction model,
287 externally validate it in their own studies with different disease outcomes and combine them with
288 other age prediction models.

289 References

- 290 1. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. *Circ Res.*
291 2012;110(8):1097-108. doi:10.1161/CIRCRESAHA.111.246876
- 292 2. Broglio SP, Eckner JT, Paulson HL, Kutcher JS. Cognitive decline and aging: the role of
293 concussive and subconcussive impacts. 2012;40(3):138.
- 294 3. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell.*
295 2013;153(6):1194-217. doi:10.1016/j.cell.2013.05.039
- 296 4. Hoffman JM, Lyu Y, Pletcher SD, Promislow DEL. Proteomics and metabolomics in ageing
297 research: from biomarkers to systems biology. *Essays Biochem.* 2017;61(3):379-88.
298 doi:10.1042/EBC20160083
- 299 5. Brooks-Wilson AR. Genetics of healthy aging and longevity. 2013;132(12):1323-38.
- 300 6. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biology.*
301 2013;14(10):3156. doi:10.1186/gb-2013-14-10-r115
- 302 7. Jansen R, Han LK, Verhoeven JE, et al. An integrative study of five biological clocks in somatic
303 and mental health. *Elife.* 2021;10. doi:10.7554/eLife.59479
- 304 8. Alonso A, Marsal S, Julia A. Analytical methods in untargeted metabolomics: state of the art
305 in 2015. *Front Bioeng Biotechnol.* 2015;3:23. doi:10.3389/fbioe.2015.00023
- 306 9. Rattray NJW, Deziel NC, Wallach JD, et al. Beyond genomics: understanding exposotypes
307 through metabolomics. *Hum Genomics.* 2018;12(1):4. doi:10.1186/s40246-018-0134-x
- 308 10. Rutledge J, Oh H, Wyss-Coray T. Measuring biological age using omics data. *Nature Reviews*
309 *Genetics.* 2022. doi:10.1038/s41576-022-00511-7
- 310 11. Martin FJ, Montoliu I, Kussmann M. Metabonomics of ageing - Towards understanding
311 metabolism of a long and healthy life. *Mech Ageing Dev.* 2017;165(Pt B):171-9.
312 doi:10.1016/j.mad.2016.12.009
- 313 12. Yu Z, Zhai G, Singmann P, et al. Human serum metabolic profiles are age dependent. *Aging*
314 *Cell.* 2012;11(6):960-7. doi:10.1111/j.1474-9726.2012.00865.x
- 315 13. Macdonald-Dunlop E, Taba N, Klarić L, et al. A catalogue of omics biological ageing clocks
316 reveals substantial commonality and associations with disease risk. *Aging.* 2022;14(2):623-59.
317 doi:10.18632/aging.203847
- 318 14. van den Akker EB, Trompet S, Barkey Wolf JJH, et al. Metabolic Age Based on the BBMRI-NL
319 (1)H-NMR Metabolomics Repository as Biomarker of Age-related Disease. *Circulation. Genomic and*
320 *precision medicine.* 2020;13(5):541-7. doi:10.1161/circgen.119.002610
- 321 15. Hertel J, Friedrich N, Wittfeld K, et al. Measuring Biological Age via Metabonomics: The
322 Metabolic Age Score. *J Proteome Res.* 2016;15(2):400-10. doi:10.1021/acs.jproteome.5b00561
- 323 16. Rist MJ, Roth A, Frommherz L, et al. Metabolite patterns predicting sex and age in
324 participants of the Karlsruhe Metabolomics and Nutrition (KarMeN) study. *PLoS One.*
325 2017;12(8):e0183228. doi:10.1371/journal.pone.0183228
- 326 17. Hwangbo N, Zhang X, Raftery D, et al. A Metabolomic Aging Clock Using Human
327 Cerebrospinal Fluid. *The Journals of Gerontology: Series A.* 2021;77(4):744-54.
328 doi:10.1093/gerona/glab212 %J The Journals of Gerontology: Series A
- 329 18. Smith G. Step away from stepwise. *Journal of Big Data.* 2018;5(1):32. doi:10.1186/s40537-
330 018-0143-6
- 331 19. Ramspek CL, Jager KJ, Dekker FW, Zoccali C, van Diepen M. External validation of prognostic
332 models: what, why, how, when and where? *Clinical Kidney Journal.* 2020;14(1):49-58.
333 doi:10.1093/ckj/sfaa188 %J Clinical Kidney Journal
- 334 20. Steyerberg EW. *Clinical Prediction Models.* 2nd ed. Cham, Switzerland: Springer
335 International Publishing; 2019.
- 336 21. Bleeker SE, Moll HA, Steyerberg EW, et al. External validation is necessary in prediction
337 research:: A clinical example. *Journal of Clinical Epidemiology.* 2003;56(9):826-32.
338 doi:[https://doi.org/10.1016/S0895-4356\(03\)00207-5](https://doi.org/10.1016/S0895-4356(03)00207-5)

- 339 22. Moore C, Sambrook J, Walker M, et al. The INTERVAL trial to determine whether intervals
340 between blood donations can be safely and acceptably decreased to optimise blood supply: study
341 protocol for a randomised controlled trial. *Trials*. 2014;15:363-. doi:10.1186/1745-6215-15-363
342 23. NHS Blood Donation Who can give blood. 2022. [https://www.blood.co.uk/who-can-give-](https://www.blood.co.uk/who-can-give-blood)
343 [blood](https://www.blood.co.uk/who-can-give-blood).
344 24. Evans A, Bridgewater B, Liu Q, et al. High resolution mass spectrometry improves data
345 quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput
346 profiling metabolomics. 2014;4(2):1.
347 25. Rhee EP, Waikar SS, Rebholz CM, et al. Variability of Two Metabolomic Platforms in CKD.
348 *Clinical Journal of the American Society of Nephrology*. 2019;14(1):40. doi:10.2215/CJN.07070618
349 26. de Mutsert R, den Heijer M, Rabelink TJ, et al. The Netherlands Epidemiology of Obesity
350 (NEO) study: study design and data collection. *Eur J Epidemiol*. 2013;28(6):513-23.
351 doi:10.1007/s10654-013-9801-3
352 27. Faquih T, van Smeden M, Luo J, et al. A Workflow for Missing Values Imputation of
353 Untargeted Metabolomics Data. *Metabolites*. 2020;10(12). doi:10.3390/metabo10120486
354 28. Hoerl AE, Kennard RW. Ridge Regression: Biased Estimation for Nonorthogonal Problems.
355 *Technometrics*. 1970;12(1):55-67. doi:10.1080/00401706.1970.10488634
356 29. Saner C, Harcourt BE, Pandey A, et al. Sex and puberty-related differences in metabolomic
357 profiles associated with adiposity measures in youth with obesity. *Metabolomics*. 2019;15(5):75.
358 doi:10.1007/s11306-019-1537-y
359 30. Hägg S, Jylhävä J. Sex differences in biological aging with a focus on human studies. *eLife*.
360 2021;10:e63425. doi:10.7554/eLife.63425
361 31. Nakamura E, Miyao K, JoGSABS, Sciences M. Sex differences in human biological aging.
362 2008;63(9):936-44.
363 32. McCrory C, Fiorito G, McLoughlin S, et al. Epigenetic clocks and allostatic load reveal
364 potential sex-specific drivers of biological aging. 2020;75(3):495-503.
365 33. Riley RD, Snell KIE, Ensor J, et al. Minimum sample size for developing a multivariable
366 prediction model: Part I - Continuous outcomes. *Statistics in medicine*. 2019;38(7):1262-75.
367 doi:10.1002/sim.7993
368 34. Copas JB. Regression, prediction and shrinkage. *Journal of the Royal Statistical Society: Series*
369 *B*. 1983;45(3):311-35.
370 35. Copas JB. Using regression models for prediction: shrinkage and regression to the mean.
371 *Statistical methods in medical research*. 1997;6(2):167-83. doi:10.1177/096228029700600206
372 36. WHO WHO. A healthy lifestyle - WHO recommendations. World Health Organization: WHO.
373 2010.
374 37. Siontis GCM, Tzoulaki I, Castaldi PJ, Ioannidis JPA. External validation of new risk prediction
375 models is infrequent and reveals worse prognostic discrimination. *Journal of Clinical Epidemiology*.
376 2015;68(1):25-34. doi:<https://doi.org/10.1016/j.jclinepi.2014.09.007>
377 38. Van Calster B, McLernon DJ, van Smeden M, et al. Calibration: the Achilles heel of predictive
378 analytics. *BMC Medicine*. 2019;17(1):230. doi:10.1186/s12916-019-1466-7

379

380

381 Funding

382 The INTERVAL study was funded by NHSBT and the NIHR Blood and Transplant Research Unit in
383 Donor Health and Genomics (NIHR BTRU-2014-10024). The trial's coordinating centre at the
384 Department of Public Health and Primary Care at the University of Cambridge, Cambridge, UK, has
385 received core support from the UK Medical Research Council (G0800270), British Heart Foundation
386 (SP/09/002), and the NIHR Cambridge Biomedical Research Centre. Investigators at the University of
387 Oxford, Oxford, UK, have been supported by the Research and Development Programme of NHSBT,
388 the NHSBT Howard Ostin Trust Fund, and the NIHR Oxford Biomedical Research Centre through the
389 programme grant NIHR-RP-PG-0310-1004. We thank the blood donors who participated in the trial
390 and NHSBT's operational staff.

391 The NEO study is supported by the participating Departments, the Division, and the Board of
392 Directors of the Leiden University Medical Centre, and by the Leiden University, Research Profile
393 Area 'Vascular and Regenerative Medicine'. The analyses of metabolites are funded by the VENI
394 grant (ZonMW-VENI Grant 916.14.023) of D.O.M.-K., D.v.H. and R.N. were supported by a grant of
395 the VELUX Stiftung [grant number 1156]. T.O.F. was supported by the King Abdullah Scholarship
396 Program and King Faisal Specialist Hospital & Research Center [No. 1012879283].

397 Conflicts of Interest

398 P.S. is an associate director of applied and statistical genetics at GlaxoSmithKline plc. R.L.-G. is a part-
399 time clinical research consultant for Metabolon, Inc. All other co- authors have no conflicts of
400 interest to declare.

401 Acknowledgments and Disclosures

402 The authors of the NEO study thank all participants, all participating general practitioners for inviting
403 eligible participants, all research nurses for data collection, and the NEO study group: Pat van
404 Beelen, Petra Noordijk, and Ingeborg de Jonge for coordination, laboratory, and data management.
405 The NEO study was approved by the medical ethical committee of the Leiden University Medical
406 Centre (LUMC) and all participants provided written informed consent.

407 Author Contributions

408 T.O.F.- conceptualization, data curation, formal analysis, investigation, methodology, software,
409 visualization, writing-original draft. R.L.-G.- validation, writing – review & editing. P.S. – supervision,
410 conceptualization, project administration, resources, funding acquisition, writing – review & editing -
411 R.d.M.- project administration, resources, funding acquisition, writing – review & editing. R.N. and
412 D.V.H.- funding acquisition, writing – review & editing. F.R.R.- funding acquisition. A.v.H.V. and
413 K.W.v.D- conceptualization, supervision, writing – review & editing. D.O.M.-K.- conceptualization,
414 supervision, funding acquisition, writing – review & editing.